Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 16:7:172.
doi: 10.3389/fendo.2016.00172. eCollection 2016.

Review of Hypoparathyroidism

Ejigayehu G Abate  1 , Bart L Clarke  2
Affiliations
Review

Review of Hypoparathyroidism

Ejigayehu G Abate et al. Front Endocrinol (Lausanne). .

Abstract

Hypoparathyroidism is a rare endocrine disorder in which parathyroid hormone (PTH) production is abnormally low or absent, resulting in low serum calcium and increased serum phosphorus. The most common cause of hypoparathyroidism is parathyroid gland injury or inadvertent removal during thyroid surgery. Current treatments include supplementation with calcium and active vitamin D, with goal albumin-corrected serum calcium level in the low-normal range of 8-9 mg/dl. Complications of the disease include renal dysfunction, nephrocalcinosis, kidney stones, extracellular calcifications of the basal ganglia, and posterior subcapsular cataracts, as well as low bone turnover and increased bone density. Until January 2015, hypoparathyroidism was the only classic endocrine disease without an available hormone replacement. Recombinant human PTH 1-84, full-length PTH, is now available for a selected group of patients with the disease who are not well controlled on the current standard therapy of calcium and active vitamin D. In addition, the role of PTH replacement on quality of life, intracerebral calcifications, cataracts, improving bone turnover, and reduction of renal complications of the disease remains to be further investigated.

Keywords: PTH (1-84); hypocalcemia; hypoparathyroidism; natpara; parathyroid hormone.

PubMed Disclaimer

References

    1. Collip JB. Clinical use of the parathyroid hormone. Can Med Assoc J (1925) 15(11):1158. - PMC - PubMed
    1. Potts JT, Jr. A short history of parathyroid hormone, its biological role, and pathophysiology of hormone excess. J Clin Densitom (2013) 16(1):4–7.10.1016/j.jocd.2012.11.002 - DOI - PubMed
    1. Aurbach GD. Isolation of parathyroid hormone after extraction with phenol. J Biol Chem (1959) 234:3179–81. - PubMed
    1. Stack BC, Jr, Bimston DN, Bodenner DL, Brett EM, Dralle H, Orloff LA, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease state clinical review: postoperative hypoparathyroidism – definitions and management. Endocr Pract (2015) 21(6):674–85.10.4158/ep14462.dsc - DOI - PubMed
    1. Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol (2013) 1(4):275–83.10.1016/S2213-8587(13)70106-2 - DOI - PubMed

LinkOut - more resources